Two long-awaited independent reviews of a controversial Medtronic Inc bone growth product show it works as well as traditional bone grafts taken from patients, but it may not be as safe.
The analyses, published on Monday in the Annals of Internal Medicine, suggest that Medtronic's Infuse product was associated with a small, increased risk of cancer, and that early published data on the trials underreported side effects and emphasized favorable results.
Last modified: Wed, 07 Aug 2013 17:32:54 BST